Study of the Atopic March: Development of Atopic Comorbidities
Background Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and sa...
Gespeichert in:
Veröffentlicht in: | Pediatric dermatology 2016-07, Vol.33 (4), p.388-398 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 398 |
---|---|
container_issue | 4 |
container_start_page | 388 |
container_title | Pediatric dermatology |
container_volume | 33 |
creator | Schneider, Lynda Hanifin, Jon Boguniewicz, Mark Eichenfield, Lawrence F. Spergel, Jonathan M. Dakovic, Rada Paller, Amy S. |
description | Background
Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety.
Methods
This was a 3‐year double‐blind study in which patients were randomized to pimecrolimus or vehicle and then open‐label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease‐free days, Eczema Area and Severity Index, and body surface area affected.
Results
Infants ages 3 to 18 months with recent‐onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus‐ and placebo‐treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar.
Conclusions
This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD. |
doi_str_mv | 10.1111/pde.12867 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5649252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1803452107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5897-a9ea6895663667b4987aa7108e596486d90c70e6b062ec9299ebef015251b9093</originalsourceid><addsrcrecordid>eNp1kD1PwzAURS0EglIY-AMoIwwB24m_GJBQgYLEpwDBZjnJKzUkdbBToP-elJYKBrx4uOddPx-EtgjeI-3ZrwvYI1RysYQ6hFEWk1TgZdTBIuGxxClfQ-shvGCMJedkFa1RQUWSJkkHHd4142ISuUHUDCE6alxt8-jS-Hx4EB3DO5SurmDUTIF52HOV85ktbGMhbKCVgSkDbM7vLno4PbnvncUX1_3z3tFFnDOpRGwUGC4V4zzhXGSpksIYQbAEpngqeaFwLjDwDHMKuaJKQQYDPP0LyRRWSRcdznrrcVZBkbcreVPq2tvK-Il2xuq_ycgO9bN714ynijLaFuzMC7x7G0NodGVDDmVpRuDGQROJk5RR0irrot0ZmnsXgofB4hmC9dS3bn3rb98tu_17rwX5I7gF9mfAhy1h8n-Tvjk--amMZxM2NPC5mDD-VbepYPrxqq9vn3jax-JRi-QLF6WXzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1803452107</pqid></control><display><type>article</type><title>Study of the Atopic March: Development of Atopic Comorbidities</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Schneider, Lynda ; Hanifin, Jon ; Boguniewicz, Mark ; Eichenfield, Lawrence F. ; Spergel, Jonathan M. ; Dakovic, Rada ; Paller, Amy S.</creator><creatorcontrib>Schneider, Lynda ; Hanifin, Jon ; Boguniewicz, Mark ; Eichenfield, Lawrence F. ; Spergel, Jonathan M. ; Dakovic, Rada ; Paller, Amy S.</creatorcontrib><description>Background
Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety.
Methods
This was a 3‐year double‐blind study in which patients were randomized to pimecrolimus or vehicle and then open‐label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease‐free days, Eczema Area and Severity Index, and body surface area affected.
Results
Infants ages 3 to 18 months with recent‐onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus‐ and placebo‐treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar.
Conclusions
This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.12867</identifier><identifier>PMID: 27273433</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Asthma - epidemiology ; Comorbidity ; Dermatitis, Atopic - drug therapy ; Dermatologic Agents - adverse effects ; Dermatologic Agents - therapeutic use ; Double-Blind Method ; Humans ; Infant ; Longitudinal Studies ; Rhinitis, Allergic - epidemiology ; Severity of Illness Index ; Tacrolimus - adverse effects ; Tacrolimus - analogs & derivatives ; Tacrolimus - therapeutic use ; Treatment Outcome</subject><ispartof>Pediatric dermatology, 2016-07, Vol.33 (4), p.388-398</ispartof><rights>2016 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5897-a9ea6895663667b4987aa7108e596486d90c70e6b062ec9299ebef015251b9093</citedby><cites>FETCH-LOGICAL-c5897-a9ea6895663667b4987aa7108e596486d90c70e6b062ec9299ebef015251b9093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpde.12867$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpde.12867$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27273433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schneider, Lynda</creatorcontrib><creatorcontrib>Hanifin, Jon</creatorcontrib><creatorcontrib>Boguniewicz, Mark</creatorcontrib><creatorcontrib>Eichenfield, Lawrence F.</creatorcontrib><creatorcontrib>Spergel, Jonathan M.</creatorcontrib><creatorcontrib>Dakovic, Rada</creatorcontrib><creatorcontrib>Paller, Amy S.</creatorcontrib><title>Study of the Atopic March: Development of Atopic Comorbidities</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>Background
Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety.
Methods
This was a 3‐year double‐blind study in which patients were randomized to pimecrolimus or vehicle and then open‐label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease‐free days, Eczema Area and Severity Index, and body surface area affected.
Results
Infants ages 3 to 18 months with recent‐onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus‐ and placebo‐treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar.
Conclusions
This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.</description><subject>Asthma - epidemiology</subject><subject>Comorbidity</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Infant</subject><subject>Longitudinal Studies</subject><subject>Rhinitis, Allergic - epidemiology</subject><subject>Severity of Illness Index</subject><subject>Tacrolimus - adverse effects</subject><subject>Tacrolimus - analogs & derivatives</subject><subject>Tacrolimus - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAURS0EglIY-AMoIwwB24m_GJBQgYLEpwDBZjnJKzUkdbBToP-elJYKBrx4uOddPx-EtgjeI-3ZrwvYI1RysYQ6hFEWk1TgZdTBIuGxxClfQ-shvGCMJedkFa1RQUWSJkkHHd4142ISuUHUDCE6alxt8-jS-Hx4EB3DO5SurmDUTIF52HOV85ktbGMhbKCVgSkDbM7vLno4PbnvncUX1_3z3tFFnDOpRGwUGC4V4zzhXGSpksIYQbAEpngqeaFwLjDwDHMKuaJKQQYDPP0LyRRWSRcdznrrcVZBkbcreVPq2tvK-Il2xuq_ycgO9bN714ynijLaFuzMC7x7G0NodGVDDmVpRuDGQROJk5RR0irrot0ZmnsXgofB4hmC9dS3bn3rb98tu_17rwX5I7gF9mfAhy1h8n-Tvjk--amMZxM2NPC5mDD-VbepYPrxqq9vn3jax-JRi-QLF6WXzg</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Schneider, Lynda</creator><creator>Hanifin, Jon</creator><creator>Boguniewicz, Mark</creator><creator>Eichenfield, Lawrence F.</creator><creator>Spergel, Jonathan M.</creator><creator>Dakovic, Rada</creator><creator>Paller, Amy S.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201607</creationdate><title>Study of the Atopic March: Development of Atopic Comorbidities</title><author>Schneider, Lynda ; Hanifin, Jon ; Boguniewicz, Mark ; Eichenfield, Lawrence F. ; Spergel, Jonathan M. ; Dakovic, Rada ; Paller, Amy S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5897-a9ea6895663667b4987aa7108e596486d90c70e6b062ec9299ebef015251b9093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Asthma - epidemiology</topic><topic>Comorbidity</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Infant</topic><topic>Longitudinal Studies</topic><topic>Rhinitis, Allergic - epidemiology</topic><topic>Severity of Illness Index</topic><topic>Tacrolimus - adverse effects</topic><topic>Tacrolimus - analogs & derivatives</topic><topic>Tacrolimus - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schneider, Lynda</creatorcontrib><creatorcontrib>Hanifin, Jon</creatorcontrib><creatorcontrib>Boguniewicz, Mark</creatorcontrib><creatorcontrib>Eichenfield, Lawrence F.</creatorcontrib><creatorcontrib>Spergel, Jonathan M.</creatorcontrib><creatorcontrib>Dakovic, Rada</creatorcontrib><creatorcontrib>Paller, Amy S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schneider, Lynda</au><au>Hanifin, Jon</au><au>Boguniewicz, Mark</au><au>Eichenfield, Lawrence F.</au><au>Spergel, Jonathan M.</au><au>Dakovic, Rada</au><au>Paller, Amy S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study of the Atopic March: Development of Atopic Comorbidities</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2016-07</date><risdate>2016</risdate><volume>33</volume><issue>4</issue><spage>388</spage><epage>398</epage><pages>388-398</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Background
Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety.
Methods
This was a 3‐year double‐blind study in which patients were randomized to pimecrolimus or vehicle and then open‐label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease‐free days, Eczema Area and Severity Index, and body surface area affected.
Results
Infants ages 3 to 18 months with recent‐onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus‐ and placebo‐treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar.
Conclusions
This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>27273433</pmid><doi>10.1111/pde.12867</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0736-8046 |
ispartof | Pediatric dermatology, 2016-07, Vol.33 (4), p.388-398 |
issn | 0736-8046 1525-1470 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5649252 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Asthma - epidemiology Comorbidity Dermatitis, Atopic - drug therapy Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Double-Blind Method Humans Infant Longitudinal Studies Rhinitis, Allergic - epidemiology Severity of Illness Index Tacrolimus - adverse effects Tacrolimus - analogs & derivatives Tacrolimus - therapeutic use Treatment Outcome |
title | Study of the Atopic March: Development of Atopic Comorbidities |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A39%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20of%20the%20Atopic%20March:%20Development%20of%20Atopic%20Comorbidities&rft.jtitle=Pediatric%20dermatology&rft.au=Schneider,%20Lynda&rft.date=2016-07&rft.volume=33&rft.issue=4&rft.spage=388&rft.epage=398&rft.pages=388-398&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.12867&rft_dat=%3Cproquest_pubme%3E1803452107%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1803452107&rft_id=info:pmid/27273433&rfr_iscdi=true |